EA199700183A1 - Способ уменьшения риска невертебральных переломов костей - Google Patents

Способ уменьшения риска невертебральных переломов костей

Info

Publication number
EA199700183A1
EA199700183A1 EA199700183A EA199700183A EA199700183A1 EA 199700183 A1 EA199700183 A1 EA 199700183A1 EA 199700183 A EA199700183 A EA 199700183A EA 199700183 A EA199700183 A EA 199700183A EA 199700183 A1 EA199700183 A1 EA 199700183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
risk
reducing
bone fractures
vertebral bone
vertebral
Prior art date
Application number
EA199700183A
Other languages
English (en)
Other versions
EA000347B1 (ru
Inventor
Артур К. II Сантора
Дэвид Б. Карпф
Дебора Р. Шапиро
Уилльям Дж. Полвино
Десмонд Е. Томпсон
Эшли Дж. Уэйтс
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27013155&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA199700183A1 publication Critical patent/EA199700183A1/ru
Publication of EA000347B1 publication Critical patent/EA000347B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Алендронат, бисфосфонат, при ежедневном введении в течение значительного периода времени, обладает способностью снижать уровень невертебральных переломов у женщин, находящихся в постклимактерическом периоде.
EA199700183A 1995-02-17 1996-02-13 Способ уменьшения риска невертебральных переломов костей EA000347B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39046295A 1995-02-17 1995-02-17
US41963195A 1995-04-10 1995-04-10
PCT/US1996/001932 WO1996025165A1 (en) 1995-02-17 1996-02-13 Method of lessening the risk of non-vertebral bone fractures

Publications (2)

Publication Number Publication Date
EA199700183A1 true EA199700183A1 (ru) 1997-12-30
EA000347B1 EA000347B1 (ru) 1999-04-29

Family

ID=27013155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700183A EA000347B1 (ru) 1995-02-17 1996-02-13 Способ уменьшения риска невертебральных переломов костей

Country Status (13)

Country Link
US (1) US5804570A (ru)
EP (1) EP0809502A4 (ru)
JP (1) JPH10504839A (ru)
KR (1) KR19980702210A (ru)
CN (1) CN1181012A (ru)
AU (1) AU690431B2 (ru)
CA (1) CA2212996A1 (ru)
EA (1) EA000347B1 (ru)
HU (1) HUP9802066A3 (ru)
NZ (1) NZ303022A (ru)
PL (1) PL321835A1 (ru)
SK (1) SK111797A3 (ru)
WO (1) WO1996025165A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
CN1196480C (zh) * 2001-07-03 2005-04-13 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗骨折的药物中的用途
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH0523134A (ja) * 1991-07-23 1993-02-02 Mitsubishi Kasei Corp 骨強度増強促進剤及びこれを含有する食品類
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
JPH0717854A (ja) * 1993-04-05 1995-01-20 Koichi Shudo 抗骨疾患剤
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
HUP9802066A3 (en) 2001-02-28
WO1996025165A1 (en) 1996-08-22
JPH10504839A (ja) 1998-05-12
CN1181012A (zh) 1998-05-06
EA000347B1 (ru) 1999-04-29
MX9706277A (es) 1997-11-29
EP0809502A4 (en) 2001-12-05
NZ303022A (en) 2000-07-28
SK111797A3 (en) 1998-02-04
PL321835A1 (en) 1997-12-22
CA2212996A1 (en) 1996-08-22
US5804570A (en) 1998-09-08
EP0809502A1 (en) 1997-12-03
AU4922796A (en) 1996-09-04
KR19980702210A (ko) 1998-07-15
AU690431B2 (en) 1998-04-23
HUP9802066A2 (hu) 2000-06-28

Similar Documents

Publication Publication Date Title
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
FR2735356B1 (fr) Implant cotyloidien destine notamment a la cavite articulaire iliaque
BG100910A (en) The use of bisphosphonates for the inhibition of osteal resorption after the implantation of orthopedic prosthesis
PL336076A1 (en) Plant extracts for treating enhanced bone resorption
IL112989A0 (en) Implant for an artificial tooth
ATE291430T1 (de) Behandlung postklimakterischer frauen unter verwendung niedrigster estrogendosen
PL321658A1 (en) Foot prosthesis
AU1615695A (en) Method for forming bone cement to an implant
DK0573604T3 (da) Fremgangsmåde til behandling af osteoporosis
CO4560546A1 (es) Formulacion con granulacion en humedo de acidos bisfosfonicos
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
EA199700185A1 (ru) Способ уменьшения риска вертебральных переломов
HUP0003957A3 (en) Method for producing calcium borate method for producing calcium borate
HUP9802529A3 (en) Method for producing calcium borate
BG103649A (en) Method for the preparation of eprosartan
ZA949563B (en) Method for treating aphthae using dimeticone.
BG103650A (en) Method for the preparation of eprosartan
GR1002665B (el) Μεθοδος για την περιποιηση φυτων.
GB9507910D0 (en) Adhesion promotion of orthopaedic implants
ZA200104140B (en) Use of ibandronate for promoting osseointegration of endoprostheses.
HUP9900659A2 (hu) Alendronát alkalmazása oszteoporózis megelőzésére
BG102780A (en) Nasal application of agents for the treatment of delayed emesis fits
NO972558D0 (no) Sett for osteoporose-behandlingssyklus
FR2733144B1 (fr) Implant pour prothese dentaire
MX9709426A (es) Uso de alendronato para preparar composiciones para la prevencion de la osteoporosis.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG TJ TM RU